Henry Schein, Inc. (NASDAQ:HSIC) Sees Significant Drop in Short Interest

Henry Schein, Inc. (NASDAQ:HSIC) saw a significant drop in short interest in the month of February. As of February 27th, there was short interest totaling 4,168,764 shares, a drop of 12.8% from the February 12th total of 4,779,133 shares. Approximately 3.7% of the company’s stock are short sold. Based on an average daily volume of 1,715,124 shares, the short-interest ratio is currently 2.4 days. Based on an average daily volume of 1,715,124 shares, the short-interest ratio is currently 2.4 days. Approximately 3.7% of the company’s stock are short sold.

Henry Schein Price Performance

NASDAQ HSIC traded up $0.44 on Tuesday, reaching $75.05. 270,256 shares of the stock traded hands, compared to its average volume of 1,403,764. The firm’s fifty day simple moving average is $78.13 and its 200 day simple moving average is $72.93. The company has a quick ratio of 0.76, a current ratio of 1.38 and a debt-to-equity ratio of 0.59. The company has a market cap of $8.61 billion, a price-to-earnings ratio of 22.93, a P/E/G ratio of 2.24 and a beta of 0.87. Henry Schein has a 12 month low of $60.56 and a 12 month high of $89.29.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, February 24th. The company reported $1.34 EPS for the quarter, topping analysts’ consensus estimates of $1.30 by $0.04. The company had revenue of $3.44 billion for the quarter, compared to the consensus estimate of $3.34 billion. Henry Schein had a return on equity of 15.16% and a net margin of 3.02%.The company’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.19 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, research analysts predict that Henry Schein will post 4.74 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Philip A. Laskawy sold 2,844 shares of Henry Schein stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $80.36, for a total value of $228,543.84. Following the completion of the transaction, the director owned 21,961 shares in the company, valued at approximately $1,764,785.96. This trade represents a 11.47% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kurt P. Kuehn sold 2,844 shares of the stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $78.96, for a total transaction of $224,562.24. Following the sale, the director directly owned 15,420 shares in the company, valued at $1,217,563.20. This trade represents a 15.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 104,556 shares of company stock valued at $8,476,351 over the last 90 days. 1.14% of the stock is owned by company insiders.

Institutional Investors Weigh In On Henry Schein

Institutional investors and hedge funds have recently bought and sold shares of the business. CYBER HORNET ETFs LLC bought a new position in shares of Henry Schein during the 2nd quarter valued at about $25,000. MUFG Securities EMEA plc acquired a new stake in Henry Schein during the second quarter valued at approximately $27,000. Flagship Harbor Advisors LLC bought a new stake in Henry Schein during the fourth quarter worth approximately $30,000. Federated Hermes Inc. bought a new stake in Henry Schein during the fourth quarter worth approximately $32,000. Finally, Los Angeles Capital Management LLC acquired a new position in Henry Schein in the fourth quarter worth approximately $37,000. 96.62% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on HSIC shares. Wells Fargo & Company boosted their price objective on Henry Schein from $76.00 to $87.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 25th. Wall Street Zen cut Henry Schein from a “strong-buy” rating to a “buy” rating in a research note on Saturday. JPMorgan Chase & Co. raised their price target on Henry Schein from $78.00 to $92.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Mizuho lifted their price objective on shares of Henry Schein from $81.00 to $88.00 and gave the company a “neutral” rating in a research note on Wednesday, February 25th. Finally, UBS Group upped their price objective on shares of Henry Schein from $79.00 to $87.00 and gave the stock a “neutral” rating in a report on Wednesday, February 25th. Six investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $85.58.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.